Trial Profile
Efficacy and safety of HBI-8000 in acute myeloid leukemia (AML) patients with AML1-ETO who has molecular relapse post allogeneic stem cell transplantation (alloSCT).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Dec 2017
Price :
$35
*
At a glance
- Drugs Tucidinostat (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 26 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology